Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Citius Oncology reported preliminary unaudited LYMPHIR unit sales of 792 units to U.S. wholesalers in fiscal Q4 2026, up 120% from 360 units in fiscal Q3, as its expanded commercial team reached nationwide coverage in August. Institutional vial orders rose modestly to 950 from 926, and 54 institutions have now ordered LYMPHIR versus 44 as of mid-August — more than halfway to the goal of 100 priority institutions on formulary by year-end. Full fiscal Q4 and FY2026 results are expected in December 2026 with the 10-K filing; figures are unaudited and subject to change.
Key figures
- Formulary goal
- 100 priority institutions by calendar year-end
- Institutions ordering
- 54
- Sequential unit growth
- 120%
- Institutions ordering prior
- 44
- Institutional vial orders q3
- 926
- Institutional vial orders q4
- 950
- Units sold to wholesalers q3 fy26
- 360
- Units sold to wholesalers q4 fy26
- 792
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.